The popular Next-Generation Sequencing-based LymphoTrack® portfolio has been expanded to include assays for the detection of IGH Somatic Hypermutation on the Ion PGM™ as well as a suite of assays which allow testing of TRG and IGH simultaneously in a single run on the MiSeq® or the Ion PGM. These assays were all designed for easy integration into a laboratory workflow and include bioinformatics software that allows for easy and streamlined data analysis. Using these assays, both the DNA sequences and frequency distributions of B- and T-cell rearrangements can be obtained. Contact us for more information.
The popular Next-Generation Sequencing-based LymphoTrack® portfolio has been expanded beyond our current MiSeq formatted product line to include assays for TRG and IGH on the Ion PGM™. These assays were designed for easy integration into the laboratory workflow, and include a bioinformatics software that allows for simple and streamlined data analysis providing both DNA sequences and frequency distributions of B- and T-cell rearrangements. Contact us for more information.
We have posted a condensed version of our AMP workshop entitled Clonality Testing by Next-Generation Sequencing: Latest Developments from the New Frontier. This talk was given to a capacity audience in Phoenix, AZ in November 2013, and now you can enjoy highlights at your own convenience. Click here to view.
Invivoscribe has expanded its portfolio of next-generation sequencing (NGS) products with the introduction of the LymphoTrack® IGH Assay (for MiSeq platform). This assay provides unprecedented levels of information in the form of frequency distributions and DNA sequences of rearranged IGH genes. Click here for more information. Contact us to learn more.
In the News
We are excited to announce that LabPMM®, our subsidiary reference laboratories in the US and the EU, now offer the only standardized, internationally harmonized and licensed FLT3 Signal Ratio Assay.
Our FLT3 signal ratio (SR) assay tests for both ITD and TKD mutations, providing signal ratios for ITD mutations by comparing the signal intensity of the mutant and wild type amplicon products.
The Feature Story in the May 2013 issue of CAP Today titled: “Molecular clonality testing for lymphoma” highlights the benefits of PCR-based B and T cell clonality assays from Invivoscribe. Click here to view the article.
LabPMM is happy to announce that we have received our New York state clinical lab license. Please contact us with any questions.
Click here to learn more about Genection.
January 8, 2014
July 16, 2013 Marketwired
June 19, 2013 Marketwired
Invivoscribe FLT3 Testing Patents Strengthened by Supreme Court Ruling